Covid 19 Research using Clinical Trials (Home Page)
basic treatmentWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug289 | Equipment with smartwatch throughout hospital stay on the general ward Wiki | 0.71 |
| drug974 | lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate Wiki | 0.71 |
| drug177 | Carrimycin Wiki | 0.71 |
| drug58 | Arbidol Wiki | 0.50 |
There are 2 clinical trials
Clinical Trials
1 Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).
In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics. In order to observe the efficacy and safety of arbidol in the treatment of 2019-ncov infected pneumonia, this study is planned.
NCT04260594 2019-nCoV Drug: Arbidol Other: basic treatment MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Measure: Virus negative conversion rate in the first week Time: first week
Secondary Outcomes
Description: virus negative conversion rate in second week, overall virus negative conversion rate
Measure: Virus negative conversion rate Time: 14-20 days
Description: defined as: the rate of Axillary temperature ≤37.5 ℃ for at least 48h
Measure: Antipyretic rate Time: 14-20 days
Description: time to relieve symptoms of fever, cough, dyspnea, myalgia, etc
Measure: Symptom relief time Time: 14-20 days
Description: no adjuvant oxygen therapy, resting oxygen saturation＞95%, oxygenation index＞350
Measure: Finger oxygen improvement rate Time: 14-20 days
Description: Mild, common type progression to severe or critical illness rate
Measure: Disease progression rate Time: 14-20 days
Measure: Mortality rate Time: 14-20 days
Measure: Incidence of severe adverse reactions Time: 14-20 days
Measure: Change curve of peripheral blood lymphocyte count Time: 14-20 days
2 The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study
Primary Outcomes
Measure: Virus negative conversion rate in the first week Time: first weekSecondary Outcomes
Description: virus negative conversion rate in second week, overall virus negative conversion rate
Measure: Virus negative conversion rate Time: 14-20 daysDescription: defined as: the rate of Axillary temperature ≤37.5 ℃ for at least 48h
Measure: Antipyretic rate Time: 14-20 daysDescription: time to relieve symptoms of fever, cough, dyspnea, myalgia, etc
Measure: Symptom relief time Time: 14-20 daysDescription: no adjuvant oxygen therapy, resting oxygen saturation＞95%, oxygenation index＞350
Measure: Finger oxygen improvement rate Time: 14-20 daysDescription: Mild, common type progression to severe or critical illness rate
Measure: Disease progression rate Time: 14-20 daysMeasure: Mortality rate Time: 14-20 days
Measure: Incidence of severe adverse reactions Time: 14-20 days
Measure: Change curve of peripheral blood lymphocyte count Time: 14-20 days
The novel coronavirus infectious disease ( COVID-19") induced by novel coronavirus(SARS-CoV-2) in December 2019 has outbreaked in Wuhan. It may lead to epidemic risk in global. As the COVID-19 is an emerging infectious disease, it has not scientifically recognized and has no effective drugs for treatment currently. Therefore, we will launch a scientific project "The efficacy and safety of carrimycin treatment in 520 patients with COVID-19 stratificated clinically: A multicenter, randomized (1:1), open-controlled (one of lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate) study" . We try to establish the criteria for clinical cure and the early predictive model of COVID-19 progression. The primary efficiency outcomes were:(1) Fever to normal time (day); (2) Pulmonary inflammation resolution time (HRCT) (day); and (3)Negative conversion (%) of SARS-CoV-2 RNA at the end of treatment. The secondary efficiency outcomes and adverse events were observed.
NCT04286503 Novel Coronavirus Infectious Disease (COVID-19) Drug: Carrimycin Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate Drug: basic treatment MeSH:Communicable Diseases Infection Coronavirus Infections
Primary Outcomes
Description: Fever to normal time (day)
Measure: Fever to normal time (day) Time: 30 daysDescription: Pulmonary inflammation resolution time (HRCT) (day)
Measure: Pulmonary inflammation resolution time (HRCT) (day) Time: 30 daysDescription: Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment
Measure: Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment Time: 30 days